Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>

שמור ב:
מידע ביבליוגרפי
מחבר ראשי: Amir T. Fathi (15313195) (author)
מחברים אחרים: Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
יצא לאור: 2025
נושאים:
Cancer
Therapeutic Research and Development
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase I clinical trials
Drug Targets
Oncoprotein & tumor suppressor drug targets
Hematological Cancers
Leukemias
Immunotherapy
Stem cell transplantation
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
תיאור
סיכום:<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>

פריטים דומים